FDA Generic GLP-1 Approval 2026: What Changes for Consumers
Everything you need to know about the FDA's progress on generic GLP-1 approvals in 2026, including semaglutide, tirzepatide, pricing, and what it means for you.
GLP-1 News & Updates
Evidence-based coverage of GLP-1 medications, telehealth, FDA updates, and clinical developments. Written by credentialed health professionals and medically reviewed.
Semaglutide Shortage Update: New Compounding Rules Take Effect June 2026
The FDA has announced new compounding regulations for GLP-1 medications. Here is what patients and telehealth providers need to know about sourcing compounded semaglutide safely.
Retatrutide Phase 3 Results: Triple Agonist Shows 24% Weight Loss at 48 Weeks
Eli Lilly has released Phase 3 clinical trial data for retatrutide, showing unprecedented weight loss results. Here is what the data means for patients and the GLP-1 market.
GLP-1 and Muscle Loss: New Research Shows Protein Protocol Can Preserve Lean Mass
A new clinical study demonstrates that a structured protein intake protocol combined with resistance exercise can significantly reduce muscle loss during GLP-1 therapy.
Subscribe to updates via our RSS feed. Never miss a clinical update or regulatory change.